Skip to content
Search

Latest Stories

Daiichi Sankyo, O’Brien’s Pharmacies collaborate to provide free AF checks in North West England

Daiichi Sankyo and O’Brien’s Pharmacies Group have joined hands to offer a free Atrial Fibrillation (AF) check to over 65s in North West England. The collaborative project, jointly funded by both the companies, aims to support the local delivery of national ambitions to improve the detection of high-risk factor conditions for cardiovascular disease, in particular AF.

The heart rhythm checks will be made available in nine O’Brien’s Pharmacies across the region. The aim will be to identify potential patients with AF in conjunction with the existing NHS Health Check service via symptoms, pulse check and AF detection device.


Where AF is suspected, the pharmacist will provide patient support and then make a referral to the patient’s GP for further investigation and provision of appropriate treatment where required. The ambition is to demonstrate the important role that community pharmacist practitioners can perform in the delivery of this health service.

Additionally, the project supports the five-year Community Pharmacy Contractual Framework to expand the role of pharmacists in the community, with a focus on detection and prevention of cardiovascular disease, and referral to treatment, in line with the NHS Long Term Plan objectives.

The NHS Long Term Plan commits to preventing 150,000 cardiovascular events by 2028, while helping to reduce the financial burden of stroke. Stroke and aftercare costs to the NHS and Social Care currently stand at approximately £0.5 billion in the North West alone.

Dr Mark Spencer, GP at Mount View Practice, Fleetwood, said: “This project is an example of how the unique contribution of community pharmacy can come together with general practice in the delivery of local health priorities. Effective detection of AF in the local area will also mean more people can learn about the condition and ultimately be better equipped to become active participants in its management.”

Lisa Cottam, Superintendent Pharmacist at O’Brien’s Pharmacies Group commented: “We encourage all patients over the age of 65 to visit their local O’Brien’s Pharmacy and speak to the pharmacist about their eligibility for a quick and easy check to detect an irregular heartbeat. With around 15,000 strokes every year in the North West, and a fifth of these accountable to AF, more needs to be done to detect and prevent the condition. We’re keen that this collaborative project will help to identify those with undiagnosed AF and ensure they can access the support and treatment they need from their GP in a timely manner, while driving conversation and awareness of cardiovascular conditions in the region.”

“Community pharmacies play a vital role in the improvement of public health and prevention, acting as the first point of contact with a healthcare professional in many people’s daily lives,” said Manuel Reiberg, Managing Director at Daiichi Sankyo UK.

“This project aligns closely with the NHS Long Term Plan ambitions, and the reach of pharmacies like O’Brien’s means they have an important part to play in reducing health inequalities in stroke prevention. We very much look forward to assessing the results and will continue to support initiatives that aim to improve timely detection and appropriate treatment of AF, which could ultimately save lives in the North West region.”

A key additional objective of the project is to help reduce health inequalities present in cardiovascular care, through greater accessibility of diagnostics in the community. Almost 90% of the population in England has access to a community pharmacy within a 20-minute walk, demonstrating the interwoven nature of pharmacies within local communities and their extensive reach to underserved groups, who may be less likely to visit their GP or another primary care service directly.

More than 23,000 people could be eligible for the AF checks, which will be available in all nine O’Brien’s Pharmacy outlets in Fleetwood, Thornton-Cleveleys, Bispham, Burscough, Liverpool and the surrounding areas. The project will run throughout 2022.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less